Viatris said on Monday it would pay up to $335 million over nine years as part of a nationwide settlement to resolve opioid-related claims against the drugmaker.
Shares of the Pennsylvania-based company, formed by the merger of Mylan and Pfizer’s Upjohn business in 2020, fell 3% in early trading.
Viatris is among several drugmakers that have faced lawsuits on claims over their role in concealing the risks of addictive pain drugs. The company sells opioid products in the form of its painkiller Ultiva and the Fentanyl Transdermal System, which is a generic version of Johnson